-
公开(公告)号：US08486895B2
公开(公告)日：2013-07-16
申请号：US13509237
申请日：2009-12-30
Applicant: David Weaver , Michael Rynkiewicz , Cheng Cao , Yanwen Jin
Inventor： David Weaver , Michael Rynkiewicz , Cheng Cao , Yanwen Jin
IPC: A61K39/00 , A61K39/395 , A61P35/00 , C07K16/22
CPC classification number: C07K16/2863 , C07K2317/92
Abstract: The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09×10−10 mol/L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.
Abstract translation: 本发明公开了具有良好结合活性（结合亲和力为5.09×10 -10 mol / L）的人源化抗表皮生长因子受体抗体，能够抑制肿瘤细胞的生长和迁移。 本发明还公开了抗体的制备方法和用途。
-
公开(公告)号：US08653244B2
公开(公告)日：2014-02-18
申请号：US13509235
申请日：2009-12-30
Applicant: David Weaver , Michael Rynkiewicz , Cheng Cao , Yanwen Jin
Inventor： David Weaver , Michael Rynkiewicz , Cheng Cao , Yanwen Jin
IPC: C07K16/00 , A61K39/395
CPC classification number: C07K16/2863 , C07K2317/24 , C07K2317/92
Abstract: The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13×10−10 mol/L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.
Abstract translation: 本发明公开了具有良好结合活性（结合亲和力为6.13×10 -10 mol / L）的人源化抗表皮生长因子受体抗体，能够抑制肿瘤细胞的生长和迁移。 本发明还公开了抗体的制备方法和用途。
-
公开(公告)号：US09028832B2
公开(公告)日：2015-05-12
申请号：US13982173
申请日：2011-03-25
Applicant: Yanwen Jin , David Weaver , Michael Rynkiewicz , Cheng Cao
Inventor： Yanwen Jin , David Weaver , Michael Rynkiewicz , Cheng Cao
IPC: C07K16/00 , A61K39/395 , C07K16/30 , C07K16/28
CPC classification number: C07K16/30 , C07K16/2863 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2317/92
Abstract: A humanized anti-EGFR antibody L4-H3 and gene encoding the antibody are disclosed. The antibody is composed of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is shown as positions 1-145 of SEQ ID NO: 3, the heavy chain constant region is the heavy chain constant region of the human antibody IgG1, and the amino acid sequence of the light chain is shown as SEQ ID NO: 1.
Abstract translation: 公开了人源化抗EGFR抗体L4-H3和编码抗体的基因。 抗体由重链和轻链组成。 重链可变区的氨基酸序列显示为SEQ ID NO：3的位置1-145，重链恒定区是人抗体IgG1的重链恒定区，轻链的氨基酸序列 如SEQ ID NO：1所示。
-
公开(公告)号：US20130022624A1
公开(公告)日：2013-01-24
申请号：US13509237
申请日：2009-12-30
Applicant: David Weaver , Michael Rynkiewicz , Cheng Cao , Yanwen Jin
Inventor： David Weaver , Michael Rynkiewicz , Cheng Cao , Yanwen Jin
IPC: A61K39/395 , C12N15/13 , A61P35/00 , C12N15/63 , C12P21/02 , A61K31/7088 , C07K16/18 , C07H21/04
CPC classification number: C07K16/2863 , C07K2317/92
Abstract: The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09×10−10 mol/L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.
Abstract translation: 本发明公开了具有良好结合活性（结合亲和力为5.09×10 -10 mol / L）的人源化抗表皮生长因子受体抗体，能够抑制肿瘤细胞的生长和迁移。 本发明还公开了抗体的制备方法和用途。
-
公开(公告)号：US20070105832A1
公开(公告)日：2007-05-10
申请号：US11398438
申请日：2006-04-04
Applicant: Thomas Bannister , Cassandra Celatka , Nizal Chandrakumar , Hongfeng Deng , Zihong Guo , Lei Jin , Tsvetelina Lazarova , Jian Lin , Scott Moe , Pamela Nagafuji , Manuel Navia , Amy Ripka , Michael Rynkiewicz , Kerry Spear , James Stickler , Roger Xie
Inventor： Thomas Bannister , Cassandra Celatka , Nizal Chandrakumar , Hongfeng Deng , Zihong Guo , Lei Jin , Tsvetelina Lazarova , Jian Lin , Scott Moe , Pamela Nagafuji , Manuel Navia , Amy Ripka , Michael Rynkiewicz , Kerry Spear , James Stickler , Roger Xie
IPC: A61K31/397 , C07D205/08
CPC classification number: C07D405/06 , C07D205/08 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/14
Abstract: Compounds are provided which have the structure Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd′ are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and thrombotic disorders.
Abstract translation: 提供具有其中A，B，C，D，m，Y，Ra，Rc，Rd和Rd'如本文所述的结构的化合物，其可用作类胰蛋白酶，凝血酶，胰蛋白酶，因子Xa， 因子VIIa，因子XIa和尿激酶型纤溶酶原激活剂，可用于预防和/或治疗哮喘，慢性哮喘，过敏性鼻炎和血栓形成障碍。
-
Patent Agency Ranking
6.发明授权公开(公告)号：US08343489B2
公开(公告)日：2013-01-01
申请号：US12293926
申请日：2007-03-21
Applicant: David T. Weaver , Michael Rynkiewicz
Inventor： David T. Weaver , Michael Rynkiewicz
IPC: A61K39/395 , C07K16/00
CPC classification number: C07K16/00 , C07K16/303 , C07K16/465 , C07K2317/24 , C07K2317/565 , C07K2317/567 , G06F19/16
Abstract: Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in humans.
Abstract translation: 本文公开的是使用三维结构信息来指导用一种或多种模板或替代物的氨基酸修饰抗体的过程，使得当保持母体抗体的抗原结合性质并且当以 治疗人类。
-
公开(公告)号：US20130330362A1
公开(公告)日：2013-12-12
申请号：US13982173
申请日：2011-03-25
Applicant: Yanwen Jin , David Weaver , Michael Rynkiewicz , Cheng Cao
Inventor： Yanwen Jin , David Weaver , Michael Rynkiewicz , Cheng Cao
IPC: C07K16/30
CPC classification number: C07K16/30 , C07K16/2863 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2317/92
Abstract: A humanized anti-EGFR antibody L4-H3 and gene encoding the antibody are disclosed. The antibody is composed of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is shown as positions 1-145 of SEQ ID NO: 3, the heavy chain constant region is the heavy chain constant region of the human antibody IgG1, and the amino acid sequence of the light chain is shown as SEQ ID NO: 1.
Abstract translation: 公开了人源化抗EGFR抗体L4-H3和编码抗体的基因。 抗体由重链和轻链组成。 重链可变区的氨基酸序列显示为SEQ ID NO：3的位置1-145，重链恒定区是人抗体IgG1的重链恒定区，轻链的氨基酸序列 如SEQ ID NO：1所示。
-
公开(公告)号：US20120321643A1
公开(公告)日：2012-12-20
申请号：US13509235
申请日：2009-12-30
Applicant: David Weaver , Michael Rynkiewicz , Cheng Cao , Yanwen Jin
Inventor： David Weaver , Michael Rynkiewicz , Cheng Cao , Yanwen Jin
IPC: C07K16/28 , C12N15/63 , C12N1/21 , C12N5/10 , C09K3/00 , C12P19/34 , A61K39/395 , A61K31/711 , A61P35/00 , C12N15/13 , C12P21/02
CPC classification number: C07K16/2863 , C07K2317/24 , C07K2317/92
Abstract: The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13×10−10 mol/L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies
Abstract translation: 本发明公开了具有良好结合活性（结合亲和力为6.13×10 -10 mol / L）的人源化抗表皮生长因子受体抗体，能够抑制肿瘤细胞的生长和迁移。 本发明还公开了抗体的制备方法和用途
-
公开(公告)号：US20090130102A1
公开(公告)日：2009-05-21
申请号：US12293926
申请日：2007-03-21
Applicant: David T. Weaver , Michael Rynkiewicz
Inventor： David T. Weaver , Michael Rynkiewicz
IPC: A61K39/395 , C07K16/00 , G06G7/58 , C12P21/00 , A61P43/00
CPC classification number: C07K16/00 , C07K16/303 , C07K16/465 , C07K2317/24 , C07K2317/565 , C07K2317/567 , G06F19/16
Abstract: Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in humans.
Abstract translation: 本文公开的是使用三维结构信息来指导用一种或多种模板或替代物的氨基酸修饰抗体的过程，使得当保持母体抗体的抗原结合性质并且当以 治疗人类。
-
公开(公告)号：US20050143317A1
公开(公告)日：2005-06-30
申请号：US10817248
申请日：2004-04-02
Applicant: Sherin Abdel-Meguid , Robert Babine , Hongfeng Deng , Lei Jin , Jian Lin , Scott Magee , Harold Meyers , Pramod Pandey , Michael Rynkiewicz , David Weaver , Zihong Gho , Thomas Bannister
Inventor： Sherin Abdel-Meguid , Robert Babine , Hongfeng Deng , Lei Jin , Jian Lin , Scott Magee , Harold Meyers , Pramod Pandey , Michael Rynkiewicz , David Weaver , Zihong Gho , Thomas Bannister
CPC classification number: C07K5/06078 , A61K38/00 , C07K5/06034 , C07K5/06139 , C07K5/06191
Abstract: The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.
Abstract translation: 本发明提供了通过向哺乳动物施用本发明的化合物来抑制因子XIa的化合物和预防或治疗不期望的血栓形成的方法。 本发明还提供了因子XIa的三维结构以及使用这些结构设计或选择另外的因子XIa抑制剂的方法。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.018 seconds)
